The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.

Published 2020 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 15_suppl, Pages 10021-10021
Publisher
American Society of Clinical Oncology (ASCO)
Online
2020-05-25
DOI
10.1200/jco.2020.38.15_suppl.10021

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.